Back A A A Font Size Receive E-mail Alerts Press Releases

Canadian Orthopedic Expert Professor Paul Beaule Visits MicroPort® Orthopedics for Academic Exchange


Shanghai, China – From September 14 to September 17, Professor Paul Beaule, Orthopedic Director of University of Ottawa Hospital, attended the 2017 Shanghai International Hip Symposium, and participated in a two-day academic exchange at the invitation of MicroPort® Orthopedics to discuss the hot topics and shared his clinical experience related to hip arthroplasty products and techniques of MicroPort® Orthopedics with over 60 orthopedic experts from several top hospitals and academic institutions in Shanghai.
On September 14, Professor Beaule attended the academic salon hosted by the Youth Committee of Shanghai Joint Surgery Society to share his personal experience with minimally invasive hip surgery techniques. The salon was chaired by Professor Chuan He of Shanghai Ruijin Hospital, who is also Head of the Youth Committee of Shanghai Joint Surgery Society. Professor Qirong Qian of Shanghai Changzheng Hospital delivered a speech to encourage young surgeons to keep practicing the minimally invasive joint arthroplasty technique to help more patients achieve faster postoperative recovery.
During the salon activity, Professor Beaule gave a lecture on the clinical follow-up outcome of MicroPort® Orthopedics hip prosthesis. He said, MicroPort® Orthopedics’ A-Class® Cross-Linked Polyethylene Liner and Profemur® TL Stem achieved outstanding result in short-term follow-up. Professor Beaule usually practices DAA technique in his minimally invasive total hip replacements. He said, Profemur® TL Stem suits not only traditional posterior approach and SuperPath™ Micro-posterior Total Hip Arthroplasty ("SuperPath™"), but anterior approach and DAA technique as well. According to his follow-up result, DAA technique has advantages over traditional posterior approach in avoiding acetabular cup aseptic loosen, dislocation, peri-prosthetic fracture and infection. In the end, Dr. Bo Wang of Changzheng Hospital analyzed reasons for proximal femoral fracture in DAA surgeries, including incomplete surrounding soft tissue release, osteoporosis, and large prosthesis, and meanwhile shared his intraoperative coping tactics. This salon attracted orthopedic experts from several top hospitals including Shanghai Changzheng Hospital, Shanghai Sixth People’s Hospital, and Shanghai Ruijin Hospital. They had hot discussions on the clinical efficacy of SuperPath™ technique and DAA technique in minimally invasive joint replacement, and shared their clinical experience respectively.
On September 15, Professor Beaule visited Shanghai Tongji Hospital for academic exchange. Professor Shuqing Wang of Shanghai Tongji Hospital introduced the development history and future plans of the Orthopedic Department of Shanghai Tongji Hospital. Afterwards, Professor Beaule released the latest clinical follow-up results of MicroPort® Orthopedics hip prosthesis and had in-depth discussions with the attendees regarding modular neck fracture. Dr. Zhitao Rao of Shanghai Tongji Hospital then exchanged ideas with Professor Beaule about the diagnosis and treatment of a complicated case of hip-spine syndrome as well as the treatment strategies of the total hip replacement.
On September 15, Professor Beaule was invited to visit the headquarters of Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®"). He was shown around MicroPort® Self-experiencing Center and briefed the company’s management philosophy, business development, technology innovation and corporate culture. Professor Beaule also had hot discussions with the R&D, manufacturing, marketing staff of MicroPort® Orthopedics regarding the design and production of hip prosthesis and instruments, and offered previous R&D suggestions based on his clinical experience.
Afterwards, Professor Beaule and experts from Shanghai Pudong Medical Association Orthopedic Special Committee attended an academic salon hosted by MicroPort® Orthopedics. MicroPort® Chief Operation Officer Glendy Wang delivered the opening speech for the salon. She said, MicroPort® will continue to host similar activities and invite more overseas experts for academic exchange to further enhance the communication between medical device providers and clinicians and thereby help promote the development of China’s healthcare industry. Professor Baoqing Yu of Shanghai Pudong Hospital said: "Minimally invasive joint replacement technique is becoming increasingly popular in China as it reduces pain and facilitates a faster return to function for patients. I hope that MicroPort® Orthopedics will organize more such kind of academic events to provide a platform for clinicians and enterprises to strengthen mutual communication and cooperation to help develop more innovative products and technologies to benefit more patient." The salon focused on the clinical follow-up data of MicroPort® Orthopedics’ hip prosthesis, surgical skills of SuperPath™ technique in hemi hip arthroplasty, and case studies of old fracture. Professor Beaule demonstrated the advantages of MicroPort® Orthopedics’ hip products with large amount of follow-up data, which further enhanced the experts’ understanding and recognition in its products.
Since it introduced SuperPath™ technique to China in 2014, MicroPort® Orthopedics has been dedicated to promoting the minimally invasive surgical technique and the fast recovery philosophy. With the commitment of helping patients return to full function faster, MicroPort® Orthopedics will continue to host various kinds of academic activities to build a communication platform for domestic and overseas orthopedic experts as well as help promote the joint surgery technique and the fast recovery philosophy.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to:

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2018 MicroPort Scientific Corporation

Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6953


[Prev]:MicroPort® CardioFlow Attends 2017 PCR London Valves
[Next]:MicroPort® Orthopedics Hosts SuperPath™ Hip Arthroplasty and Fast Recovery Seminar